News & Blog

As many interstitial cystitis (IC) and bladder pain syndrome (BPS) patients may have heard, Aquinox has halted its development program for rosiptor (AQX-1125).  The purpose of the LEADERSHIP 301 trial was to assess the effect of once-daily rosiptor (AQX-1125) on bladder pain and urinary symptoms in people with IC/BPS.

Although this news is disappointing, the ICA is heartened by the US Food and Drug Administration’s (FDA) continued support for research and guidance toward developing drugs for patients with IC/BPS.  Although this clinical trial did not produce results as expected, Aquinox was able to share information with the FDA that can be applied to direct future research and efforts toward finding new drugs to treat the condition.

While finding and testing new drugs to treat IC/BPS remains a challenge, remember that there are a variety of treatment options that are available that have already been studied and proven to be beneficial. An individualized combination of treatments coming from a multidisciplinary medical team yields the best results in symptom reduction.

Please visit the ICA’s website (www.ichelp.org) for the most current and up-to-date information on ongoing research, advocacy opportunities, and treatment options for IC/BPS.